4 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 4 of 4 clinical reviews.
Full FDA approval history for Jardiance (empagliflozin), including original NDA, supplemental approvals for cardiovascular and heart failure indications, label expansions, and post-market safety updates.
A complete guide to Jardiance (empagliflozin) regulatory history worldwide, covering FDA approval dates, label changes, EMA authorization, post-market safety data, and current prescribing guidance.
Every FDA label change for Jardiance (empagliflozin) from 2020 through 2026, including new indications for heart failure, chronic kidney disease, and updated safety warnings.
A complete analysis of Jardiance (empagliflozin) legal disputes, patent challenges, FDA approval history, label expansions, and post-market safety actions from 2014 through 2026.